The New England journal of medicine, 2022-10, Vol.387 (17), p.1557-1568
- Gross, Neil D.
- Miller, David M.
- Khushalani, Nikhil I.
- Divi, Vasu
- Ruiz, Emily S.
- Lipson, Evan J.
- Meier, Friedegund
- Su, Yungpo B.
- Swiecicki, Paul L.
- Atlas, Jennifer
- Geiger, Jessica L.
- Hauschild, Axel
- Choe, Jennifer H.
- Hughes, Brett G.M.
- Schadendorf, Dirk
- Patel, Vishal A.
- Homsi, Jade
- Taube, Janis M.
- Lim, Annette M.
- Ferrarotto, Renata
- Kaufman, Howard L.
- Seebach, Frank
- Lowy, Israel
- Yoo, Suk-Young
- Mathias, Melissa
- Fenech, Keilah
- Han, Hyunsil
- Fury, Matthew G.
- Rischin, Danny
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Gross, Neil D.
- Miller, David M.
- Khushalani, Nikhil I.
- Divi, Vasu
- Ruiz, Emily S.
- Lipson, Evan J.
- Meier, Friedegund
- Su, Yungpo B.
- Swiecicki, Paul L.
- Atlas, Jennifer
- Geiger, Jessica L.
- Hauschild, Axel
- Choe, Jennifer H.
- Hughes, Brett G.M.
- Schadendorf, Dirk
- Patel, Vishal A.
- Homsi, Jade
- Taube, Janis M.
- Lim, Annette M.
- Ferrarotto, Renata
- Kaufman, Howard L.
- Seebach, Frank
- Lowy, Israel
- Yoo, Suk-Young
- Mathias, Melissa
- Fenech, Keilah
- Han, Hyunsil
- Fury, Matthew G.
- Rischin, Danny
- Titel
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
- Ist Teil von
- The New England journal of medicine, 2022-10, Vol.387 (17), p.1557-1568
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- Elektronische Zeitschriftenbibliothek (Open access)
- Beschreibungen/Notizen
- A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2209813Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9844515
- Format
- –
- Schlagworte
- Adverse events, Antineoplastic Agents, Immunological - administration & dosage, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, Cancer therapies, Carcinoma, Squamous Cell - drug therapy, Carcinoma, Squamous Cell - pathology, Carcinoma, Squamous Cell - surgery, Clinical medicine, Dermatology, Hematology, Humans, Hypotheses, Immunotherapy, Laboratories, Metastasis, Monoclonal antibodies, Neoadjuvant Therapy, Neoplasm Staging, Oncology, Patients, Pharmaceuticals, Pilot Projects, Quality of life, Radiation therapy, Remission Induction, Skin Cancer, Skin Neoplasms - drug therapy, Skin Neoplasms - pathology, Skin Neoplasms - surgery, Squamous cell carcinoma, Surgery, Targeted cancer therapy, Treatments in Oncology, Tumor cells